Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker-Directed Phase 2 Trial of SY-1425 in Adult Patients with AML or MDS
2024-516281-11-00Phase 2Completed
- Sponsor
- Syros Pharmaceuticals
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tamibarotene in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (6 arms), sponsored by Syros Pharmaceuticals. Primary endpoints: Overall response rate (ORR) for biomarker positive patients with AML or higher-risk MDS, Transfusion independence rate (TIR) for lower-risk MDS and 1 more. Started Sep 2024; status: completed.
02
Drugs
tamibarotene
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2024-516281-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516281-11-00.